Meeting
2023 ASCO Annual Meeting
Multimodal detection in plasma of molecular residual disease (MRD) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC).
Authors
Enrique Sanz Garcia
Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
Enrique Sanz Garcia , Jinfeng Zou , Lisa Avery , Anna Spreafico , John Waldron , David Paul Goldstein , Aaron Richard Hansen , John Cho , John R de Almeida , Andrew Hope , Ali Hosni , Ezra Hahn , Bayardo Perez-Ordonez , Zhen Zhao , Christopher Gareth Smith , Yangqiao Zheng , Nitzan Rosenfeld , Nittusha Singaravelan , Scott Victor Bratman , Lillian L. Siu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Local-Regional Disease
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 6065)
DOI
10.1200/JCO.2023.41.16_suppl.6065
Abstract #
6065
Poster Bd #
57
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
XRay Vision: A phase 3 study of xevinapant plus radiotherapy (RT) for high-risk, cisplatin-ineligible patients with resected, locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).
First Author: Robert L. Ferris
Poster
2024 ASCO Annual Meeting
Longitudinal circulating tumor DNA monitoring in predicting response to short-course neoadjuvant radiotherapy in locally advanced rectal cancer: Data from a phase III clinical trial (UNION).
First Author: Zhenyu Lin
Poster
2023 ASCO Annual Meeting
Correlation of CDKN2A genomic alterations with tumor response to palbociclib given before chemoradiation therapy (CRT) to patients with human papillomavirus (HPV)-negative, locally advanced head and neck squamous-cell carcinoma (LA-HNSCC): A single-arm, phase 2 trial.
First Author: Peter John Oppelt
Poster
2022 ASCO Annual Meeting
Analysis of circulating tumor DNA in the phase 2 BTCRC LUN 16-081 trial of consolidation nivolumab with or without ipilimumab after chemoradiation in stage III non–small cell lung cancer.
First Author: Soyeong Jun